MOLN: Molecular Partners AG - Summary | Jitta

Molecular Partners AG

NASDAQ:MOLN

Price
$6.96
Loss Chance
49.4%
1.99JITTA SCORE
62.18%Under Jitta Line
Jitta Ranking
196 / 604
564 / 1,197
3,724 / 5,062
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (40)
Recent Business Performance (86)
Financial Strength (51)
Return to Shareholders (18)
Competitive Advantage (33)
Jitta Signs
Recent IPOLess than 3 years
Revenue and EarningEarning loss detected in 2021
Operating MarginInconsistent
CapExVery High
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
1.99
62.18%
1.31
116.13%
2.00
242.70%
Biotechnology
6.10
57.99%
5.54
31.11%
3.95
71.78%
COMPANY DESCRIPTION
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.